Q2 EPS Estimate for Voyager Therapeutics Reduced by Analyst

Voyager Therapeutics, Inc. (NASDAQ:VYGR) – Investment analysts at HC Wainwright lowered their Q2 2026 EPS estimates for shares of Voyager Therapeutics in a research note issued on Tuesday, May 26th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.48) for the quarter, down from their previous forecast of ($0.28). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($1.61) EPS, Q1 2027 earnings at ($0.29) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.30) EPS, Q4 2027 earnings at ($0.28) EPS, FY2027 earnings at ($1.18) EPS, FY2028 earnings at ($1.63) EPS, FY2029 earnings at ($1.38) EPS and FY2030 earnings at ($0.94) EPS.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.07. Voyager Therapeutics had a negative net margin of 319.61% and a negative return on equity of 55.97%. The company had revenue of $1.19 million for the quarter, compared to the consensus estimate of $8.79 million.

VYGR has been the topic of a number of other reports. Truist Financial upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 25th. Wall Street Zen downgraded shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a research report on Wednesday, April 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $3.93 on Thursday. The firm’s 50-day moving average is $3.91 and its 200-day moving average is $3.99. Voyager Therapeutics has a 1 year low of $2.64 and a 1 year high of $5.55. The company has a market cap of $237.45 million, a P/E ratio of -1.99 and a beta of 1.26.

Insiders Place Their Bets

In related news, CEO Alfred Sandrock sold 11,511 shares of Voyager Therapeutics stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $3.87, for a total value of $44,547.57. Following the sale, the chief executive officer directly owned 472,549 shares in the company, valued at $1,828,764.63. This trade represents a 2.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 12.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

Several hedge funds have recently bought and sold shares of VYGR. Wexford Capital LP bought a new stake in Voyager Therapeutics in the 3rd quarter valued at about $42,000. ProShare Advisors LLC bought a new stake in Voyager Therapeutics in the 4th quarter valued at about $44,000. CIBC Asset Management Inc bought a new stake in Voyager Therapeutics in the 4th quarter valued at about $45,000. Coldstream Capital Management Inc. bought a new stake in Voyager Therapeutics in the 3rd quarter valued at about $55,000. Finally, EHP Funds Inc. bought a new stake in Voyager Therapeutics in the 3rd quarter valued at about $58,000. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.